Eine klinische Studie zur Beurteilung einer Emicizumab-Prophylaxe im Vergleich zu keiner Prophylaxe bei Hämophilie-A-Patient*innen ohne Hemmkörper

A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors (HAVEN 3)

  • Hämophilie
  • Hämophilie A
Bitte beachten Sie, dass der Rekrutierungsstatus der Studie an Ihrem Standort vom Gesamtstatus der Studie abweichen kann, da einige Studienzentren früher rekrutieren als andere.
Status der Studie:

Abgeschlossen

Diese Studie läuft in
Stadt
  • Bonn
Studien-ID:

NCT02847637 2016-000072-17 HAVEN3 BH30071

      Studienzentren finden

      Die folgenden Informationen stammen aus der öffentlich zugänglichen Website ClinicalTrials.gov und werden für Laien bearbeitet.

      Die folgenden Informationen stammen aus der öffentlich zugänglichen Website ClinicalTrials.gov und werden nicht geändert.

      Results Disclaimer

      Studienzusammenfassung

      This is a randomized, global, multicenter, open-label, Phase 3 clinical study in participants with severe hemophilia A without inhibitors against Factor VIII (FVIII) who are 12 years or older. The study evaluates two prophylactic emicizumab regimens versus no prophylaxis in this population with emphasis on efficacy, safety, and pharmacokinetics.

      Hoffmann-La Roche Sponsor
      Phase 3 Phase
      NCT02847637, BH30071, 2016-000072-17, HAVEN3 Studien-ID
      Emicizumab, Factor VIII (FVIII) Treatments
      Hemophilia A Condition
      Official Title

      A Randomized, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Patients Without Inhibitors

      Einschlusskriterien

      All Gender
      ≥12 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Body weight >/= 40 kilogram (kg) at the time of screening
      • Diagnosis of severe congenital hemophilia A
      • Documentation of the details of prophylactic or episodic FVIII treatment and of number of bleeding episodes for at least the last 24 weeks
      • Adequate hematologic function
      • Adequate hepatic function
      • Adequate renal function
      • For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of less than (<) 1 percent (%) per year during the treatment period and for at least 5 elimination half-lives (24 weeks) after the last dose of study drug
      Exclusion Criteria
      • Inherited or acquired bleeding disorder other than hemophilia A
      • Previous or current treatment for thromboembolic disease or signs of thromboembolic disease
      • Conditions that may increase risk of bleeding or thrombosis
      • History of clinically significant hypersensitivity associated with monoclonal antibody therapies or components of the emicizumab injection
      • Known human immunodeficiency virus (HIV) infection with cluster of differentiation (CD) 4 count <200 cells per microliter (cells/mcL) within 24 weeks prior to screening. Participants with HIV infection who has CD4 greater than (>) 200 and meet all other criteria are eligible
      • Use of systemic immunomodulators at enrollment or planned use during the study, with the exception of anti-retroviral therapy
      • Participants who are at high risk for thrombotic microangiopathy (TMA) (for example, have a previous medical or family history of TMA), in the investigator's judgment
      • Concurrent disease, treatment, or abnormality in clinical laboratory tests that could interfere with the conduct of the study, may pose additional risk, or would, in the opinion of the investigator, preclude the participant's safe participation in and completion of the study
      • Planned surgery (excluding minor procedures) during the study
      • Receipt of emicizumab in a prior investigational study; an investigational drug to treat or reduce the risk of hemophilic bleeds within 5 half-lives of last drug administration; a non-hemophilia-related investigational drug concurrently, within last 30 days or 5 half-lives, whichever is shorter
      • Pregnant or lactating, or intending to become pregnant during the study

      Um die aktuellste Version dieser Seite aufzurufen gehen Sie bitte auf www.Klinische-studien-für-patienten.de

       

      Über klinische Studien

      Erfahren Sie mehr über klinische Studien und wie sie durchgeführt werden

      Erfahren Sie mehr